ABBV 119
Alternative Names: ABBV-119Latest Information Update: 05 Jul 2023
At a glance
- Originator AbbVie
- Class Antifibrotics
- Mechanism of Action Cystic fibrosis transmembrane conductance regulator modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Cystic fibrosis
Most Recent Events
- 22 Jun 2023 Abbvie terminates a phase-II clinical trial in Cystic fibrosis (Combination therapy, In adults) due to strategic conditions in United Kingdom, Slovakia, Hungary, Germany, Australia, New Zealand, Czech Republic, Netherlands, Belgium and USA (PO) (NCT04853368)
- 24 Oct 2022 Abbvie completes enrollments in a Phase-II clinical trial in Cystic fibrosis (Combination therapy, In adults) in United Kingdom, Slovakia, Hungary, Germany, Australia, New Zealand, Czech Republic, Netherlands, Belgium and USA (PO) (NCT04853368)
- 20 Sep 2021 Phase-II clinical trials in Cystic fibrosis (Combination therapy, In adults) in United Kingdom, Slovakia, Hungary, Germany, Netherlands, Belgium and USA (PO) (NCT04853368)